MaaT Pharma (Microbiota as a Therapy) (Euronext: MAAT)

https://www.maatpharma.com

LinkedIn: https://www.linkedin.com/company/maat-pharma

MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating a range of cancers and Graft-versus-Host-Disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into improving outcomes of immunotherapy in solid tumors, we have built a powerful discovery and analysis platform, GutPrint®, to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiomerelated conditions. Our biotherapeutics are produced under the strictest cGMP manufacturing and quality control process to safely deliver the full diversity and functionality of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead the integration of microbiome treatment into clinical practice. *

	Start	2014-01-01 established
	Industry	BIOTECH
	Industry 2	microbial therapy
	Person	Affagard, Hervé (MaaT Pharma 201507 CEO)
	Person 2	Bernal, Savita (MaaT Pharma 202005– CBO before Adocia + e(ye)BRAIN + Ernst & Young Paris)

	Region	Lyon
	Country	France
	Street	317 avenue Jean Jaurès
	City	69007 Lyon
	Tel	+33-4-2829-1400
		Address record changed: 2024-01-05

Basic data	Employees	B: 11 to 50 (2021-10-01)
	Currency	EUR
	Annual sales	2,136,000 (income, other (2020) 2020-12-31)
	Profit	-5,301,000 (2020-12-31)
	Cash	19,913,000 (2020-12-31)

		* Document for »About Section«: MaaT Pharma. (2/5/20). "Press Release: MaaT Pharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics". Lyon.

		Record changed: 2024-02-12

Picture Swiss Biotech Association Global Village 2025 SBD25 Basel 650x200px

More documents for MaaT Pharma (Microbiota as a Therapy) (Euronext: MAAT)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)